What are the current recommendations for tranexamic acid (TXA) use, including timing, dosing, and contraindications, in trauma patients with significant hemorrhage?

Tranexamic Acid in Trauma: Current Evidence-Based Recommendations

Administer tranexamic acid 1 g IV bolus over 10 minutes followed by 1 g infusion over 8 hours to all adult trauma patients with significant hemorrhage (SBP <90 mmHg or HR >110 bpm) or at risk of significant bleeding, ideally within the first hour but no later than 3 hours post-injury. 1, 2

Timing: The Critical Window

The timing of TXA administration is absolutely critical and directly impacts mortality outcomes:

• Within 1 hour of injury: Maximum benefit with 32% reduction in hemorrhage-related mortality (RR 0.68,95% CI 0.57-0.82) 2
• Between 1-3 hours: Still beneficial with 21% reduction in hemorrhage-related mortality (RR 0.79,95% CI 0.64-0.97) 2
• After 3 hours: Treatment effect disappears and may actually increase risk of death from hemorrhage (RR 1.44,95% CI 1.12-1.84) 1

Recent 2025 evidence from the PATCH-Trauma trial suggests the optimal window may be even narrower at 90 minutes, with benefit most pronounced up to this timepoint 3. However, the established 3-hour cutoff remains the current standard based on the most robust guideline evidence 1, 2, 4.

Dosing Regimen

Standard protocol 1, 2:

• Loading dose: 1 g IV over 10 minutes
• Maintenance: 1 g IV infusion over 8 hours
• Infusion rate: No faster than 1 mL/minute to avoid hypotension 5

Alternative dosing considerations: The STAAMP trial suggests repeated dosing up to 3 g total may be considered in hypotensive patients 1, though the standard 2 g total dose remains the guideline recommendation. A 2025 comparative analysis found equivalent outcomes between 1 g bolus only, 1 g + 1 g infusion, and 2 g bolus strategies, suggesting single bolus administration may be preferable to avoid complexity 6.

Patient Selection Criteria

Administer TXA to patients with:

• Systolic blood pressure <90 mmHg, OR
• Heart rate >110 bpm, OR
• Clinical judgment that patient is at risk of significant hemorrhage 1

Critical point: Do NOT restrict TXA to only the most severely injured patients. The mortality benefit is consistent regardless of baseline probability of death, meaning all patients meeting hemorrhage criteria should receive it 1.

Prehospital Administration

Consider initiating TXA en route to hospital to ensure administration within the critical time window 2, 4. The 2025 joint position statement from NAEMSP, ACEP, and ACS-COT supports prehospital TXA administration after lifesaving interventions in adult trauma patients with hemorrhagic shock 7, 8.

Absolute Contraindications

Do NOT administer TXA in 5:

• Subarachnoid hemorrhage (risk of cerebral edema and infarction)
• Active intravascular clotting
• Known hypersensitivity to tranexamic acid

Route-specific warning: TXA is for IV use ONLY. Inadvertent intrathecal administration has caused seizures and cardiac arrhythmias 5.

Safety Profile

The safety data is reassuring:

• No increase in thromboembolic events: CRASH-2 actually showed lower rates of thrombosis with TXA, and PATCH trial found no difference in thrombotic events (23.6% TXA vs 19.7% placebo) 1
• Seizure risk: Primarily reported with high-dose cardiac surgery use (10-fold higher than trauma doses) or inadvertent neuraxial administration 5
• No treatment-related adverse effects reported in CRASH-2 1

Special Populations

Renal impairment: Dose reduction required 5:

• Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
• Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
• Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours

Pediatric patients: No established prehospital dosing or evidence base. If used, must be within 3 hours of injury 7.

Traumatic brain injury: CRASH-3 showed benefit in mild-moderate TBI when given within 3 hours (RR 0.78,95% CI 0.64-0.95), but not in severe TBI 1.

Critical Pitfalls to Avoid

1. Do not wait for laboratory confirmation of hyperfibrinolysis before administering TXA. Clinical criteria alone are sufficient, and waiting for viscoelastic testing delays treatment beyond the therapeutic window 4.

2. Do not administer after 3 hours post-injury - this is associated with harm, not benefit 1, 2, 1.

3. Do not withhold from less severely injured patients - benefit is consistent across injury severity spectrum 1.

4. Communicate TXA administration clearly to receiving facilities to avoid duplicate dosing and ensure appropriate monitoring 7.

5. Avoid concomitant prothrombotic agents (Factor IX concentrates, anti-inhibitor coagulant concentrates, hormonal contraceptives) as they may increase thrombotic risk 5.

Implementation Algorithm

1. Identify trauma patient with SBP <90 mmHg, HR >110 bpm, or clinical concern for significant bleeding
2. Check time from injury - if >3 hours, do NOT give TXA
3. Verify no contraindications (subarachnoid hemorrhage, active clotting, hypersensitivity)
4. Administer 1 g IV bolus over 10 minutes (no faster than 1 mL/min)
5. Follow with 1 g infusion over 8 hours
6. Document and communicate to receiving team

The evidence strongly supports early TXA administration as a simple, cost-effective intervention that reduces trauma mortality by approximately 1.5% overall and by one-third in patients with life-threatening hemorrhage 1, 2.